Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 14/20 | 0.76 |
| ▸ | ESR1 | P03372 | 13/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | TOP1 | P11387 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7502682 | 1.00 | HRAS (0.76) | HRASESR1ESR2HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL4621620 | 0.99 | HRAS (0.76) | HRASESR1ESR2HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL7511681 | 0.99 | HRAS (0.76) | HRASESR1ESR2HDAC1HDAC2 | |
| SCHEMBL7510593 | 0.95 | HRAS (0.69) | HRASESR1ESR2HDAC1HDAC2 | |
| SCHEMBL7514039 | 0.95 | HRAS (0.69) | HRASESR1ESR2HDAC1HDAC2 | |
| SCHEMBL7506821 | 0.95 | HRAS (0.69) | HRASESR1ESR2HDAC1HDAC2 | |
| SCHEMBL7505515 | 0.95 | HRAS (0.69) | HRASESR1ESR2HDAC1HDAC2 | |
| SCHEMBL7574089 | 0.95 | HRAS (0.69) | HRASESR1ESR2HDAC1HDAC2 | |
| SCHEMBL7504409 | 0.95 | HRAS (0.69) | HRASESR1ESR2HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL7569463 | 0.94 | HRAS (0.69) | HRASESR1ESR2HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396851-B2 | Heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin A for the treatment of β-thalassaemia | UNIVERSITA' DEGLI STUDI DI FERRARA (IT) | 2008-07-08 | — | — | US | claimed |
| US-20040259799-A1 | Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia | ASSOCIAZIONE VENETA PER LA LOTTA ALLA TALASSEMIA (IT) | 2004-12-23 | — | — | US | claimed |
| EP-0722446-B1 | DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS | PHARMACIA ITALIA SPA (IT) | 2002-12-11 | — | — | EP | claimed |
| US-7396851-B2 | Heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin A for the treatment of β-thalassaemia | UNIVERSITA' DEGLI STUDI DI FERRARA (IT) | 2008-07-08 | — | — | US | disclosed |
| US-7396851-B2 | Heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin A for the treatment of β-thalassaemia | UNIVERSITA' DEGLI STUDI DI FERRARA (IT) | 2008-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259799-A1 | Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia | HBZ, HBG2, HBB | HRAS 3056/4885ESR1 4577/4885ESR2 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.